ArticleHealth affairs scholar2026
Advancing the measurement of favorable selection in Medicare Advantage: evidence from encounter data.
Article in Health affairs scholar, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction: Debate persists over how favorable selection in Medicare Advantage (MA) affects federal spending relative to Traditional Medicare (TM). Prior studies, including the Medicare Payment Advisory Commission's (MedPAC's) March 2025 Report, focus on TM-to-MA switchers-roughly one-third of MA enrollees-but extrapolating these findings to the broader MA population is sensitive to identifying assumptions because switchers' cost patterns may differ from non-switchers. This study uses MA encounter data to compare switchers and non-switchers and assess an alternative extrapolation approach to estimating favorable selection. Methods: We estimated favorable selection among 1.4 million MA enrollees from 2020 to 2022, generating separate estimates for switchers and non-switchers. Using a 5% national Medicare sample, we attempted to replicate MedPAC's switcher-based analysis, then modified its extrapolation by comparing risk-adjusted costs (imputed with TM claims) between switchers and non-switchers using MA encounter data. Results: Favorable selection ranged from 4.9% to 5.8% between 2020 and 2022-32% to 40% lower than our attempted replication of MedPAC's estimate (8.2%-8.8%). Conclusion: Using an alternative extrapolation approach lowered favorable selection, underscoring its sensitivity to methods and the importance of further refinement for MA payment policy.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.